PF
Peter Feinberg
Director

Peter Feinberg insider trades: Immuneering (IMRX) stock purchases

Director, Immuneering Last trade Jan 12, 2026 21 Form 4 filings
$0
Sold, last 12 months
0 sales
$87K
Bought, last 12 months
1 buy
12
Open-market trades
since 2021
2
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Peter reports to the SEC

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jan 12, 2026IMRX↑ Buy$87K
Oct 3, 2025IMRX↑ Buy$50K
Sep 30, 2025IMRX↑ Buy$53K
Sep 29, 2025IMRX↑ Buy$36K
Jun 18, 2025IMRX↑ Buy$63K
Mar 22, 2024IMRX↑ Buy$64K
Mar 19, 2024IMRX↑ Buy$183K
Mar 15, 2022IMRX↑ Buy$45K
Sep 20, 2021IMRX↑ Buy$116K
Sep 13, 2021IMRX↑ Buy$124K
Sep 13, 2021IMRX↑ Buy$7K
Aug 3, 2021IMRX↑ Buy$4.4M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other IMRX insiders

Open-market trades in the last 12 months

About Peter Feinberg's insider trades

Peter Feinberg is a director at Immuneering (IMRX). Since Aug 3, 2021, Peter has reported 12 open-market purchases worth $5.2M and no sales on SEC Form 4. In the last 12 months: 1 buy ($87K).

Their filings also include grants and awards (10 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IMRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.